. Author manuscript; available in PMC: 2015 Dec 15.

Published in final edited form as: Arch Biochem Biophys. 2014 Oct 19;0:244–253. doi: 10.1016/j.abb.2014.10.006

Table 3.

Preferred model mechanism and parameters for steady-state glucuronidation of R- and S-7-hydroxywarfarin by HLM150^a

Substrate	Metabolites^b	Model^c	Parameters for Preferred Model
Substrate	Metabolites^b	Model^c	V_max1^d	V_max2^d	K_s (μM)	K_ss (μM)
R-7-HOWAR	7-HOWAR-4-GLUC	Substrate Inhibition	58.0 (49.5–66.1)	19.0 (16.3–21.4)	145 (112–183)	145 (112–183)
R-7-HOWAR	7-HOWAR-7-GLUC	Michaelis-Menten	1090 (1050–1140)	-	121 (101–144)	-
S-7-OHWAR	7-HOWAR-4-GLUC	Substrate Inhibition	19.7 (17.6–22.4)	-	110 (83.0–149)	2850 (1950–4400)
S-7-OHWAR	7-HOWAR-7-GLUC	Substrate Inhibition	1470 (1020–2700)	-	927 (559–1960)	1310 (538–2810)

The nonsymmetrical 95 % confidence intervals for parameters are shown in parentheses.

Glucuronidation resulted in conjugation of the hydroxyl group at either the C4 or C7 position resulting in the formation of 7-HOWAR-4-GLUC or 7-HOWAR-7-GLUC, respectively, as described in the Discussion.

See Table 3 for details for the specific metabolic mechanism describing formation of the respective glucuronides metabolites.

Units are nmol/min/mg protein.